financetom
Business
financetom
/
Business
/
Switzerland seeks trade deal with Trump without getting into EU bind
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Switzerland seeks trade deal with Trump without getting into EU bind
Jul 3, 2025 9:17 AM

*

Switzerland threatened by higher US tariffs than EU

*

Swiss recently agreed major trade overhaul with EU

*

Dollar weakness vs franc also hurting Swiss exporters

By Dave Graham

ZURICH, July 3 (Reuters) - Switzerland is exploring what

concessions it can make to secure a deal with Washington on

trade, but it must tread carefully to protect its interests with

key trading partner, the European Union, politicians and people

familiar with the matter said.

The Swiss cabinet last month approved its biggest trade

policy overhaul in years with the EU, two months after the U.S.

stunned Switzerland by announcing 31% tariffs - well above the

20% rate Washington set out for the 27-nation bloc.

That shock prompted a scramble by business leaders and

officials to underline how much Switzerland invests in the

United States and the tariff threat was suspended for a 90-day

period ending July 9. Talks are continuing.

Nicolas Walder, a Greens member of the lower house of

parliament's foreign policy committee, said Switzerland must

insist on its commitment to multilateralism with the U.S.

"A deal should not interfere with any agreement that

Switzerland has signed or wants to sign, and should specifically

mention the bilateral agreement with the EU," said Walder, whose

committee is regularly briefed on the trade talks.

The Swiss mandate for negotiating with the U.S. stipulates

that relations with its other trade partners be upheld. Any U.S.

deal must be compatible with Switzerland's future relations with

the EU, a Swiss source familiar with the matter said.

Swiss officials and lawmakers believe that a 31% tariff can

be averted, but say U.S. President Donald Trump's existing 10%

baseline tariff looks likely to stay.

"Switzerland is negotiating in good faith with the U.S.

government, aiming for a positive outcome," the Swiss Economy

Ministry said in a statement in response to questions on the

points made by Reuters in this article.

The EU trade agreement faces a lengthy approval process and

is almost certain to be put to a national referendum under

Switzerland's system of direct democracy.

CONCESSIONS

Trump's unpredictable approach to trade policy has been a

challenge for Switzerland, which abolished its own industrial

tariffs last year and sets great store by adherence to rules.

Eager to offer Trump something, Switzerland is exploring

granting concessions to the U.S., such as greater market access

for produce like seafood and citrus fruits, the source said.

Home to pharmaceutical giants Roche and Novartis - both big

U.S. investors - Switzerland also knows Washington has been

investigating trade practices in the sector and does not want

any deal to be muddied later by pharma tariffs, the source said.

"This is absolutely crucial," said Simon Michel, a federal

lawmaker and CEO of medical technology company Ypsomed.

Jean-Philippe Kohl, deputy director of industry association

Swissmem, said even if only a 10% tariff applies, the dollar's

decline against the Swiss franc amid the trade uncertainty was

already making exporters' goods dearer in the U.S.

And if the EU secured better tariff terms with Washington,

that could put Swiss firms at a disadvantage.

"It's therefore important that the dialogue with the U.S.

quickly lead to a positive outcome," he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors
Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors
Mar 26, 2025
09:59 AM EDT, 03/26/2025 (MT Newswires) -- Exelixis ( EXEL ) said Wednesday it received approval for Cabometyx for patients with previously treated advanced neuroendocrine tumors from the US Food and Drug Administration. The approval was for the treatment of patients 12 years of age and older with previously treated, unresectable, pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors. The company...
Toyo Doubling Production Capacity at Solar Cell Facility in Ethiopia
Toyo Doubling Production Capacity at Solar Cell Facility in Ethiopia
Mar 26, 2025
09:52 AM EDT, 03/26/2025 (MT Newswires) -- Toyo (TOYO) said Wednesday morning it plans to expand solar cell capacity in Ethiopia by building another 2 gigawatts of capacity in the country, doubling production capacity at the Hawassa facility. Formal construction is expected to begin next month and conclude in July, with Toyo currently conducting equipment installation, testing and trial runs...
Rivian Doubles Down On EV Innovation With Micromobility Spin-Off, Stock Gains
Rivian Doubles Down On EV Innovation With Micromobility Spin-Off, Stock Gains
Mar 26, 2025
Rivian Automotive, Inc. ( RIVN ) announced on Wednesday that it has spun off its micromobility business into a new company, Also, Inc. The company’s shares saw an uptick on Wednesday following the announcement. This move will allow Also to focus on developing small, lightweight electric vehicles designed to address the global mobility challenges. Rivian’s venture into micromobility began as...
BlackRock launches new model portfolio to further private market push
BlackRock launches new model portfolio to further private market push
Mar 26, 2025
(Reuters) - BlackRock ( BLK ) has launched its first model portfolio blending private and publicly traded assets, it said on Wednesday, as it looks to expand its footprint in the lucrative private market landscape. Model portfolios are blueprints that financial advisers use to manage their clients' investments. Tailored for a variety of risk tolerances and goals, they can help...
Copyright 2023-2026 - www.financetom.com All Rights Reserved